[1] GREB JE, GOLDMINZ AM, ELDER JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
[2] ARMSTRONG AW, READ C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.
[3] OBRADORS M, BLANCH C, COMELLAS M, et al. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25(11):2739-2754.
[4] TAKESHITA J, GREWAL S, LANGAN SM, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017; 76(3):393-403.
[5] ALQASSIMI S, ALBRASHDI S, GALADARI H, et al. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566-571.
[6] PARISI R, ISKANDAR IYK, KONTOPANTELIS E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
[7] 陈朝霞,李萍,张广中,等.艾灸治疗血瘀证斑块型银屑病:随机对照研究[J].中国针灸,2021,41(7):762-766.
[8] 陈日新.热敏灸实用读本[M].北京:人民卫生出版社,2009.
[8] 滑宬.从唐容川理论探讨三焦实质[J].北京中医药,2015,34(8): 641-643.
[9] 宋兴.陈潮祖教授“膜腠三焦”说[J].成都中医药大学学报,1994(2): 6-9.
[10] 欧阳厚淦,赵志东,卢文静,等.热敏灸对骨质疏松症大鼠筋膜中ERK1/2的影响[J].河南中医,2014,34(6):1039-1040.
[11] YANG L, LI B, DANG E, et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci. 2016;81(2):85-92.
[12] NOGUEIRA M, PUIG L, TORRES T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341-352.
[13] SANO S, CHAN KS, CARBAJAL S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11(1):43-49.
[14] 高扬,孙文,高艳峰,等.银屑1号下调小鼠银屑病模型炎性因子及NF-κB表达的调控机制[J].中国皮肤性病学杂志,2017,31(10): 1131-1134.
[15] CHEN RX, LV ZM, CHEN MR, et al. Stroke treatment in rats with tail temperature increase by 40-min moxibustion. Neurosci Lett. 2011; 503(2):131-135.
[16] 曹翠香,侯海静,李其林.消退素D1对咪喹莫特诱导的小鼠银屑病模型的治疗作用[J].中国皮肤性病学杂志,2019,33(3):275-279.
[17] NESTLE FO, KAPLAN DH, BARKER J. Psoriasis. N Engl J Med. 2009;361(5): 496-509.
[18] 巢元方.诸病源候论[M].北京:人民军医出版社,2006:369-370.
[19] 李艳,杨文信,胡荣毅,等.中药麻黄对寻常型银屑病小鼠血清IFN-γ、IL-17的影响[J].西南医科大学学报,2021,44(5):571-575.
[20] 宋颖,朱世文,王晓馨.不同剂量雷公藤多苷对寻常型银屑病样小鼠血清炎性因子的影响[J].安徽医药,2021,25(10):1934-1938.
[21] 张帅,杨志波,唐雪勇,等.金黄膏走罐辅助凉血平银饮治疗银屑病的临床效果[J].中国医药导报,2019,16(6):133-136.
[22] 吴盘红,刘爱民,王丽,等.火针联合刺络拔罐干预稳定期轻度寻常型银屑病血瘀证[J].中医学报,2021,36(5):1111-1115.
[23] 蒋岚.针刺治疗寻常型头皮银屑病的随机对照临床研究[D].北京:北京中医药大学,2021.
[24] 马瑜婕.针灸综合治疗(轻中度)斑块型银屑病的临床研究[D].北京:北京中医药大学,2021.
[25] 姚荷生,姚梅龄,姚芷龄.三焦焦膜病辨治[J].江西中医学院学报, 2007,19(4):1-5.
[26] 邓丙戌,姜春燕,王萍,等.银屑病的中医证候分布及演变规律[J].中医杂志,2006,47(10):770-772.
[27] 欧阳彦楚.基于三焦焦膜实质对热敏灸治疗银屑病机制的实验研究[D].南昌:江西中医药大学,2020.
[28] KAGAMI S. IL-23 and Th17 cells in infections and psoriasis. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(1):13-19.
[29] ZHOU L, IVANOV II, SPOLSKI R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967-974.
[30] NISHIHARA M, OGURA H, UEDA N, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol. 2007;19(6):695-702.
[31] HEINRICH PC, BEHRMANN I, MÜLLER-NEWEN G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334( Pt 2)(Pt 2):297-314.
[32] RÉBÉ C, VÉGRAN F, BERGER H, et al. STAT3 activation: A key factor in tumor immunoescape. JAKSTAT. 2013;2(1):e23010.
[33] SIMANSKI M, RADEMACHER F, SCHRÖDER L, et al. IL-17A and IFN-γ synergistically induce RNase 7 expression via STAT3 in primary keratinocytes. PLoS One. 2013;8(3):e59531.
|